神経損傷(Nerve Injury)の治療薬パイプライン動向(2015年上半期版)

◆英語タイトル:Nerve Injury - Pipeline Review, H1 2015
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC6075IDB
◆発行日:2015年1月22日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[神経損傷(Nerve Injury)の治療薬パイプライン動向(2015年上半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における神経損傷(Nerve Injury)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・神経損傷(Nerve Injury)の概要
・神経損傷(Nerve Injury)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・神経損傷(Nerve Injury)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・神経損傷(Nerve Injury)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・神経損傷(Nerve Injury)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Nerve Injury – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Nerve Injury – Pipeline Review, H1 2015’, provides an overview of the Nerve Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nerve Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nerve Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Nerve Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Nerve Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nerve Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nerve Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nerve Injury Overview 7
Therapeutics Development 8
Pipeline Products for Nerve Injury – Overview 8
Pipeline Products for Nerve Injury – Comparative Analysis 9
Nerve Injury – Therapeutics under Development by Companies 10
Nerve Injury – Therapeutics under Investigation by Universities/Institutes 11
Nerve Injury – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nerve Injury – Products under Development by Companies 14
Nerve Injury – Products under Investigation by Universities/Institutes 15
Nerve Injury – Companies Involved in Therapeutics Development 16
Acorda Therapeutics, Inc. 16
Calico LLC 17
Convergence Pharmaceuticals Ltd. 18
F. Hoffmann-La Roche Ltd. 19
Kolon Life Science, Inc. 20
Medtronic, Inc. 21
Neuralstem, Inc. 22
Neurotune AG 23
Pfizer Inc. 24
Nerve Injury – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
3K3A-APC – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cimaglermin alfa – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CLP-257 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CNV-1014802 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
KLS-Nst – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MDT-15 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NSI-566 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NT-1654 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Activate NAMPT for Neurological Disorders – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
WAY-258131 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Nerve Injury – Recent Pipeline Updates 49
Nerve Injury – Dormant Projects 58
Nerve Injury – Discontinued Products 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

[List of Tables]
Number of Products under Development for Nerve Injury, H1 2015 8
Number of Products under Development for Nerve Injury - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Nerve Injury - Pipeline by Acorda Therapeutics, Inc., H1 2015 16
Nerve Injury - Pipeline by Calico LLC, H1 2015 17
Nerve Injury - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 18
Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19
Nerve Injury - Pipeline by Kolon Life Science, Inc., H1 2015 20
Nerve Injury - Pipeline by Medtronic, Inc., H1 2015 21
Nerve Injury - Pipeline by Neuralstem, Inc., H1 2015 22
Nerve Injury - Pipeline by Neurotune AG, H1 2015 23
Nerve Injury - Pipeline by Pfizer Inc., H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Nerve Injury Therapeutics - Recent Pipeline Updates, H1 2015 49
Nerve Injury - Dormant Projects, H1 2015 58
Nerve Injury - Discontinued Products, H1 2015 59

[List of Figures]
Number of Products under Development for Nerve Injury, H1 2015 8
Number of Products under Development for Nerve Injury - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

*** 掲載企業 ***

Acorda Therapeutics, Inc.
Calico LLC
Convergence Pharmaceuticals Ltd.
F. Hoffmann-La Roche Ltd.
Kolon Life Science, Inc.
Medtronic, Inc.
Neuralstem, Inc.
Neurotune AG
Pfizer Inc.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※H&Iグローバルリサーチは調査サービスを通じて、お客様の海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをご提供しております。
※当市場調査資料"神経損傷(Nerve Injury)の治療薬パイプライン動向(2015年上半期版)"は"Global Markets Direct社"が調査・発行しており、H&Iグローバルリサーチが販売します。お気軽にお問い合わせください。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。